These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29914097)

  • 1. Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.
    Mostafa AA; Meyers DE; Thirukkumaran CM; Liu PJ; Gratton K; Spurrell J; Shi Q; Thakur S; Morris DG
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29914097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
    Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
    Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
    Rajani K; Parrish C; Kottke T; Thompson J; Zaidi S; Ilett L; Shim KG; Diaz RM; Pandha H; Harrington K; Coffey M; Melcher A; Vile R
    Mol Ther; 2016 Feb; 24(1):166-74. PubMed ID: 26310630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
    Feola S; Capasso C; Fusciello M; Martins B; Tähtinen S; Medeot M; Carpi S; Frascaro F; Ylosmäki E; Peltonen K; Pastore L; Cerullo V
    Oncoimmunology; 2018; 7(8):e1457596. PubMed ID: 30221051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
    Samson A; Scott KJ; Taggart D; West EJ; Wilson E; Nuovo GJ; Thomson S; Corns R; Mathew RK; Fuller MJ; Kottke TJ; Thompson JM; Ilett EJ; Cockle JV; van Hille P; Sivakumar G; Polson ES; Turnbull SJ; Appleton ES; Migneco G; Rose AS; Coffey MC; Beirne DA; Collinson FJ; Ralph C; Alan Anthoney D; Twelves CJ; Furness AJ; Quezada SA; Wurdak H; Errington-Mais F; Pandha H; Harrington KJ; Selby PJ; Vile RG; Griffin SD; Stead LF; Short SC; Melcher AA
    Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.
    Annels NE; Simpson GR; Denyer M; Arif M; Coffey M; Melcher A; Harrington K; Vile R; Pandha H
    Mol Ther Oncolytics; 2021 Mar; 20():434-446. PubMed ID: 33665363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
    Oseledchyk A; Ricca JM; Gigoux M; Ko B; Redelman-Sidi G; Walther T; Liu C; Iyer G; Merghoub T; Wolchok JD; Zamarin D
    Oncotarget; 2018 Jun; 9(47):28702-28716. PubMed ID: 29983890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory.
    Veinalde R; Pidelaserra-Martí G; Moulin C; Jeworowski LM; Küther L; Buchholz CJ; Jäger D; Ungerechts G; Engeland CE
    Mol Ther Oncolytics; 2022 Mar; 24():43-58. PubMed ID: 34977341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.
    Woller N; Gürlevik E; Fleischmann-Mundt B; Schumacher A; Knocke S; Kloos AM; Saborowski M; Geffers R; Manns MP; Wirth TC; Kubicka S; Kühnel F
    Mol Ther; 2015 Oct; 23(10):1630-40. PubMed ID: 26112079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
    Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
    J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
    Zamarin D; Ricca JM; Sadekova S; Oseledchyk A; Yu Y; Blumenschein WM; Wong J; Gigoux M; Merghoub T; Wolchok JD
    J Clin Invest; 2018 Apr; 128(4):1413-1428. PubMed ID: 29504948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local Delivery of OncoVEX
    Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
    Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
    [No Abstract]   [Full Text] [Related]  

  • 19. Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade.
    Miri SM; Ebrahimzadeh MS; Abdolalipour E; Yazdi M; Hosseini Ravandi H; Ghaemi A
    Cancer Cell Int; 2020; 20():380. PubMed ID: 32782438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.